FundingValneva received a new grant from CEPI providing up to $41.3M of additional funding.
PartnershipsValneva announced a new partnership with the Serum Institute of India to supply the vaccine in Asia.
Regulatory ApprovalsIxchiq has received marketing authorization from the Brazilian Health Regulatory Agency for the prevention of disease caused by the chikungunya virus in individuals 18 years of age and older.
Bears Say
Regulatory ChallengesValneva has assumed all further R&D, CMC, and regulatory activities for potential worldwide commercialization of S4V2.
RisksRisks include commercial, regulatory, development, manufacturing, financial/dilution, and liability.
What was Valneva’s price range in the past 12 months?
Valneva lowest stock price was $3.62 and its highest was $8.66 in the past 12 months.
What is Valneva’s market cap?
Valneva’s market cap is $485.98M.
When is Valneva’s upcoming earnings report date?
Valneva’s upcoming earnings report date is Aug 12, 2025 which is in 32 days.
How were Valneva’s earnings last quarter?
Valneva released its earnings results on May 07, 2025. The company reported -$0.136 earnings per share for the quarter, beating the consensus estimate of -$0.278 by $0.142.
What happened to Valneva’s price movement after its last earnings report?
Valneva reported an EPS of -$0.136 in its last earnings report, beating expectations of -$0.278. Following the earnings report the stock price went up 1.698%.
Which hedge fund is a major shareholder of Valneva?
Currently, no hedge funds are holding shares in VALN
Valneva SE is a specialty vaccine company focused on the development and commercialization of prophylactic vaccines for infectious diseases. The company operates primarily in the biotechnology and pharmaceuticals sectors, with a core focus on delivering vaccines for diseases with significant unmet medical needs, including Lyme disease, chikungunya, and COVID-19.
VALN Company Deck
VALN Earnings Call
Q1 2025
1.0x
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call presented a mix of positive financial performance with significant revenue growth and improved gross margins, alongside challenges related to safety concerns for IXCHIQ and an operating loss. The overall sentiment is balanced, reflecting both substantial achievements and notable challenges.Read More>